Advertisement

Vakzinationskonzepte: Offene Fragen und Perspektiven

  • Gerold Schuler
Part of the Onkologie aktuell book series (ONKAKTUELL)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5: 296–306PubMedCrossRefGoogle Scholar
  2. Bonifaz LC, Bonnyay DP, Charalambous A et al. (2004) In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 199: 815–824PubMedCrossRefGoogle Scholar
  3. Carralot JP, Probst J, Hoerr I, Scheel B, Teufel R, Jung G, Rammensee HG, Pascolo S (2004) Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol Life Sci 61: 2418–2424PubMedCrossRefGoogle Scholar
  4. Davis ID, Chen W, Jackson H, Parente P et al. (2004) Recombinant NYESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 101: 10697–10702PubMedCrossRefGoogle Scholar
  5. Dudley ME, Wunderlich JR, Yang JC et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346–2357PubMedCrossRefGoogle Scholar
  6. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137–148PubMedCrossRefGoogle Scholar
  7. Ganss R, Arnold B, Hammerling GJ (2004) Mini-review: overcoming tumor-intrinsic resistance to immune effector function. Eur J Immunol 34: 2635–2641PubMedCrossRefGoogle Scholar
  8. Gerloni M, Zanetti M (2005) CD4 T cells in tumor immunity. Springer Seminars in Immunopathology 27:37–48PubMedCrossRefGoogle Scholar
  9. Germeau C, Ma W, Schiavetti F, Lurquin C et al. (2005) High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 201: 241–248PubMedCrossRefGoogle Scholar
  10. Heit A, Schmitz F, O’Keeffe M, Staib C, Busch DH, Wagner H, Huster KM (2005) Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J Immunol 174: 4373–4380PubMedGoogle Scholar
  11. Klebanoff CA, Gattinoni L, Torabi-Parizi P et al. (2005) Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 102: 9571–9576PubMedCrossRefGoogle Scholar
  12. Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wolfel C, Huber C, Wolfel T (2005) The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 102: 16013–16018PubMedCrossRefGoogle Scholar
  13. Lurquin C, Lethe B, De Plaen E, Corbiere V, Theate I, van Baren N, Coulie PG, Boon T (2005) Contrasting frequencies of antitumor and antivaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 201: 249–257PubMedCrossRefGoogle Scholar
  14. O’Rourke MG, Johnson M, Lanagan C et al. (2003) Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 52: 387–395PubMedGoogle Scholar
  15. Pasare C, Medzhitov R (2005) Toll-like receptors: linking innate and adaptive immunity, Adv Exp Med Biol 560: 11–18PubMedCrossRefGoogle Scholar
  16. Phan GQ, Yang JC, Sherry RM et al. (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100: 8372–8377PubMedCrossRefGoogle Scholar
  17. Rivoltini L, Castelli C, Carrabba M, Mazzaferro V et al. (2003) Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma-and colon carcinoma-specific T cells. J Immunol 171: 3467–3474PubMedGoogle Scholar
  18. Rosenberg SA, Sherry RM, Morton KE et al. (2005) Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 1:175(9) 6169–6176Google Scholar
  19. Rossi M, Young JW (2005) Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J Immunol 175: 1373–1381PubMedGoogle Scholar
  20. Schadendorf D, Ugurel S, Schuler-Thurner B et al. (2006) Dacarbazine (DTIC) versus Vaccination with Autologous Peptide-pulsed Dendritic Cells (DC) in First-line Treatment of Patients with Metastatic Melanoma: a Randomized Phase III Trial of the DC Study Group of the DeCOG. Annals Oncol 17: 563–570CrossRefGoogle Scholar
  21. Schuler G (2004) Grundlagen der Immunologie und Allergologie. In: Dermatologie und Venerologie, 2. Aufl. Springer, Berlin Heidelberg New York, S 43–64Google Scholar
  22. Shevach EM (2004) Fatal attraction: tumors beckon regulatory T cells. Nat Med 10: 900–901PubMedCrossRefGoogle Scholar
  23. Speiser DE, Lienard D, Rufer N (2005) Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115: 739–746PubMedCrossRefGoogle Scholar
  24. Wynn TA (2005) T(H)-17: a giant step from T(H)1 and T(H)2. Nat Immunol 6: 1069–1070PubMedCrossRefGoogle Scholar
  25. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5: 263–274PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag Heidelberg 2006

Authors and Affiliations

  • Gerold Schuler
    • 1
  1. 1.Dermatologische Klinik mit PoliklinikUniversitätsklinikum ErlangenErlangen

Personalised recommendations